Adjuvance Technologies Announces First Clinical Results of its Next-generation Saponin Adjuvant
Adjuvance Technologies Inc., a privately held clinical-stage biopharmaceutical company developing saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced that its adjuvant TQL-1055 was safe and well-tolerated with a co-administered pertussis vaccine. This is the first clinical trial of a candidate from the company’s adjuvant and vaccine portfolio.
“The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. Our semi-synthetic molecule is designed to overcome these limitations,” said Tyler Martin M.D., Chief Executive Officer at Adjuvance. “These promising interim results demonstrate the potential of TQL-1055, including its ability to be used in a broader dose-range without compromising its excellent tolerability.”
Interim data from the trial show that TQL-1055 was generally well tolerated across all dose levels, with an overall safety profile similar to a commercial pertussis vaccine. Solicited events reported by subjects included mild to moderate injection site reactions and mild or moderate systemic symptoms at a frequency similar to the commercial vaccine. No serious adverse events were reported.
The ongoing phase 1, randomized, double-blind, active-controlled, dose-escalation study is assessing the safety and immunogenicity of Pertussis Acellular Vaccine Adjuvanted with TQL-1055 (PAVA). It has fully enrolled 72 healthy adults 18-50 years of age and is evaluating six escalating dose levels from 25 to 800 mcg of TQL-1055, co-administered with a commercial pertussis vaccine. The primary endpoints of the study are safety and tolerability. Further data will be presented at IDWeek 2021.
About Pertussis: Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination.
About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21 that is designed to have improved tolerability and provide the same strong immune response as QS-21. Adjuvance has retained the desirable properties of, and eliminated several challenges with QS-21. TQL-1055 is a semi-synthetic molecule whose efficient synthesis uses raw material from leaves and branches of the Quillaja saponaria tree, making it available in greater quantities than the source material for other saponin adjuvants. TQL-1055 has shown favorable tolerability and a strong immune response in a clinical trial. With TQL-1055 as the foundation, Adjuvance is designing new combination adjuvants to produce different types of immune responses.
About saponin adjuvants: Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against shingles, malaria, COVID-19 and influenza. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.
About Adjuvance Technologies: Adjuvance Technologies is a privately held clinical-stage biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our vaccine candidates in pertussis and herpes zoster aim to provide a better experience for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210824005212/en/
Contact information
Investors
Tyler Martin
Chief Executive Officer
+1 402-817-5050
Media
Melissa Malhame
mmalhame@adjuvancetechnologies.com
+1 531-530-1287
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phenom Named Strategic Leader in 2025 Fosway 9-Grid™ for Talent & People Success for Second Consecutive Year29.10.2025 15:30:00 EET | Press release
Phenom, an applied AI company that helps organizations hire faster, develop better and retain longer, has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029195746/en/ Phenom has been named a Strategic Leader in the 2025 Fosway 9-Grid™ for Talent and People Success for the second consecutive year, changing their position by demonstrating increased performance for enterprises while lowering the total cost of ownership. The placement is a testament to the value delivered by its AI, automation and experience approach. Fosway Group identifies Strategic Leaders as companies that provide a ric
Andersen Consulting Adds Collaborating Firm Vivaldi29.10.2025 15:30:00 EET | Press release
Andersen Consulting announces a Collaboration Agreement with Vivaldi, a global business and brand strategy consultancy, strengthening the organization’s strategy and business transformation offerings. Founded in 1999, Vivaldi is known for its approach to converge brand, business, and technology to keep clients in their leadership position. Operating in the U.S., Europe, and Latin America, Vivaldi works with leading global companies to build strong market positions, accelerate innovation, and design customer-centric business models. In today’s fast-evolving world shaped by AI, platform dynamics, and continuous reinvention, Vivaldi helps clients reimagine how business value is created and captured. The firm’s multidisciplinary teams blend deep consumer insight and market foresight with strategic, creative, and financial rigor to deliver tailored solutions for growth, transformation, and long-term competitiveness across industries. “Today’s business landscape demands that organizations le
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota ®29.10.2025 15:00:00 EET | Press release
As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota® (faecal microbiota, live – jslm). To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota®. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients. Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota® was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease. Ferring
GigaDevice GD32F5xx and GD32G5xx Software Test Libraries (STL) Receive TÜV Rheinland IEC 61508 Functional Safety Certification29.10.2025 15:00:00 EET | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, announced that its GD32F5xx and GD32G5xx Software Test Libraries have received IEC 61508 SC3 (SIL 2/SIL 3) functional safety certification from TÜV Rheinland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029124621/en/ Certificate This milestone expands GigaDevice’s functional safety portfolio, which already includes the GD32H7 and GD32F30x STLs, and now covers a broad range of MCUs with Arm® Cortex®-M7, Cortex®-M4, and Cortex®-M33 cores. Building on this foundation, GigaDevice will continue to deliver high-performance and safety-focused hardware and software solutions for key applications such as industrial control, energy and power, and humanoid robotics. With the growing emphasis on safety across industries like industrial automation, functional safety has become a critical considerat
375ai Launches Data Layer for the Physical World on Solana29.10.2025 15:00:00 EET | Press release
375ai, an edge data intelligence company transforming the physical world into structured, machine-readable insights, today announced the launch of its mainnet on Solana. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028976994/en/ 375ai Launches Data Layer for the Physical World The physical world is generating more data than ever before, but most of it is invisible. Traffic systems, advertising platforms, and governments still rely on outdated infrastructure and fragmented data sources to understand how people and goods move through cities. Centralized data pipelines are expensive, slow, and often limited to incomplete or delayed insights. Meanwhile, AI systems are hungry for real world context not just synthetic inputs. Without structured, real time data, they can’t power smarter mobility, logistics, and safety solutions. 375ai enables real world data capture, unlocking a new category of physical AI infrastructure. At l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom